A game changing LATITUDE: Role of abiraterone plus prednisolone in metastatic hormone-sensitive prostate cancer

A game changing LATITUDE: Role of abiraterone plus prednisolone in metastatic hormone-sensitive prostate cancer

Bibliographic Details
Main Author:	Aditya Prakash Sharma
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2017-01-01
Series:	Indian Journal of Urology
Online Access:	http://www.indianjurol.com/article.asp?issn=0970-1591;year=2017;volume=33;issue=4;spage=333;epage=334;aulast=Sharma

Similar Items

Erratum: A game changing LATITUDE: Role of abiraterone plus prednisolone in metastatic hormonesensitive prostate cancer
Published: (2019-01-01)

Docetaxel, abiraterone, enzalutamide, apalutamide in patients with metastatic hormone-sensitive prostate cancer
by: Harkirat Singh Talwar
Published: (2021-01-01)

Abiraterone acetate in combination with prednisone in the treatment of metastatic hormone-sensitive prostate cancer: clinical evidence and experience
by: Karin Purshouse, et al.
Published: (2019-01-01)

A real‐world comparison of docetaxel versus abiraterone acetate for metastatic hormone‐sensitive prostate cancer
by: Igor Tsaur, et al.
Published: (2021-09-01)

Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer
by: Pedro Nazareth Aguiar Jr., et al.

Abiraterone acetate versus bicalutamide in combination with gonadotropin releasing hormone antagonist therapy for high risk metastatic hormone sensitive prostate cancer
by: Takashi Ueda, et al.
Published: (2021-05-01)

STAMPEDEing metastatic prostate cancer: CHAARTing the LATITUDEs
by: Aditya Prakash Sharma, et al.
Published: (2018-01-01)

Efficacy of Taxotere, Thalidomide, and Prednisolone in Patients with Hormone-Resistant Metastatic Prostate Cancer
by: Hamid Rezvani, et al.
Published: (2012-11-01)

Abiraterone in the treatment of metastatic castration-resistant prostate cancer
by: Mostaghel EA
Published: (2014-01-01)

Replacing prednisolone with dexamethasone to overcome the resistance to abiraterone in castration-resistant prostate cancer: a clinical case
by: A. A. Meshcheryakov, et al.
Published: (2020-07-01)

Impact of pretreatment anemia on upfront abiraterone acetate therapy for metastatic hormone-sensitive prostate cancer: a multicenter retrospective study
by: Teppei Okamoto, et al.
Published: (2021-05-01)

Real-world experience with abiraterone in metastatic castration-resistant prostate cancer
by: Yasar Ahmed, et al.
Published: (2017-01-01)

Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer
by: Zobniw CM, et al.
Published: (2014-08-01)

Abiraterone acetate and docetaxel with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer in China: an indirect treatment comparison and cost analysis
by: Xin Hu, et al.
Published: (2019-12-01)

Corticosteroid switch from prednisone to dexamethasone in metastatic castration-resistant prostate cancer patients with biochemical progression on abiraterone acetate plus prednisone
by: Zhenyu Yang, et al.
Published: (2021-08-01)

Abiraterone acetate for early stage metastatic prostate cancer: patient selection and special considerations
by: Castellan P, et al.
Published: (2018-12-01)

PSA flare in metastatic castration-resistant prostate cancer patients treated with abiraterone or docetaxel
by: Hui-Ying Liu, et al.
Published: (2016-06-01)

Hormonal Therapeutics Enzalutamide and Abiraterone Acetate in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel—an Indirect Comparison
by: Pui S. Tan, et al.
Published: (2014-03-01)

Hormonal Therapeutics Enzalutamide and Abiraterone Acetate in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel—an Indirect Comparison
by: Pui S. Tan, et al.
Published: (2014-01-01)

Living with Advanced Hormone-Sensitive Prostate Cancer and Treatment with Abiraterone and Androgen Deprivation Therapy: The Patient, Nursing and Physician Perspective
by: Tony Collier, et al.
Published: (2020-10-01)

Population-Based Study of Docetaxel or Abiraterone Effectiveness and Predictive Markers of Progression Free Survival in Metastatic Castration-Sensitive Prostate Cancer
by: Juan Briones, et al.
Published: (2021-05-01)

Adherence Measures for Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate plus Prednisone: Results of a Prospective, Cluster-Randomized Trial
by: Henrik Suttmann, et al.
Published: (2020-09-01)

Abiraterone acetate plus LHRH therapy versus abiraterone acetate while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer (SPARE): study protocol for a randomized controlled trial
by: Carsten-Henning Ohlmann, et al.
Published: (2017-10-01)

Role of systemic chemotherapy in metastatic hormone-sensitive prostate cancer
by: Niraj Shenoy, et al.
Published: (2016-01-01)

The role of chemohormonal therapy in metastatic hormone sensitive prostate cancer
by: Ravindran Kanesvaran, et al.
Published: (2015-12-01)

Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer
by: Ayşe Demirci, et al.
Published: (2021-07-01)

Influence of treatment with abiraterone and enzalutamide on development of sarcopenia in patients with metastatic castration resistant prostate cancer
by: S. Fischer, et al.
Published: (2020-07-01)

Feasibility of abiraterone acetate treatment in patients with metastatic castration-resistant prostate cancer and atrial fibrillation
by: Simon Rauch, et al.
Published: (2016-06-01)

Impact of abiraterone on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives
by: El-Amm J, et al.
Published: (2017-07-01)

Clinically complete response to abiraterone acetate in a patient with metastatic castration‐resistant prostate cancer
by: Yoshinori Yanai, et al.
Published: (2019-07-01)

An experience with abiraterone as treatment for metastatic castration-resistant prostate cancer: Changhua christian hospital experience
by: Wan-yun Fang, et al.
Published: (2016-06-01)

The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone
by: Martin Boegemann, et al.
Published: (2017-02-01)

Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer
by: Joshua P. Schiff, et al.
Published: (2019-05-01)

Usage, effectiveness and safety of abiraterone in prostate cancer
by: J. M. Caro Teller, et al.
Published: (2014-03-01)

Pharmacoeconomic analysis of enzalutamide and abiraterone for treatment of chemotherapy naive patients with metastatic castration resistant prostate cancer
by: N. A. Avxentyev, et al.
Published: (2017-10-01)

A tertiary care audit of using abiraterone acetate in patients of metastatic castrate-resistant prostate cancer
by: Amit Joshi, et al.
Published: (2020-01-01)

Cytoreductive radiotherapy combined with abiraterone in metastatic castration-resistance prostate cancer: a single center experience
by: Yang Liu, et al.
Published: (2021-01-01)

Influence of Statins on Survival Outcome in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Abiraterone Acetate.
by: Martin Boegemann, et al.
Published: (2016-01-01)

Clinical appraisal of abiraterone in the treatment of metastatic prostatic cancer: patient considerations, novel opportunities, and future directions
by: Mitsiades N, et al.
Published: (2013-01-01)

The efficacy of abiraterone acetate in treating Taiwanese chemo-refractory metastatic castration-resistant prostate cancer patients
by: Tony Wu, et al.
Published: (2016-12-01)

Cannot write session to /tmp/vufind_sessions/sess_cu2tac86h71gjn3rdgec8eur14